knowledge -WSS

knowledge

author：knowledge 2025-08-04 12:34:05 - browse：3

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Beyond aggravation: Constipation is an American epidemic

knowledge

WSS

A $475,000 price tag for a new cancer drug: crazy or meh?

Congress: Prevent baby formula shortages by passing a new bill

Cybersecurity threat forces Lurie Children's to take systems offline

U.S. death rates show how politics are affecting public health

Biden administration opens offers in Medicare drug price negotiations

Why we need mandatory labeling of GMO products

entertainment

knowledge

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What we need to know about Arena Bioworks

How to save PrEP access — and even expand it

Quicker fix for pulse oximeters urged during FDA public meeting

Virginia high school admissions case could be legal follow

Unmasking the 'centricity' illusion in clinical trials

Drug repurposing or repositioning? The language matters

The Bio Revolution is changing business and society

hotspot

Quicker fix for pulse oximeters urged during FDA public meeting

The Bio Revolution is changing business and society

Unmasking the 'centricity' illusion in clinical trials

New research sheds light on how often breast cancer is overdiagnosed

SAMSHA loosens regulations on methadone treatment centers

Asahi Kasei to buy Calliditas, picking up kidney disease drug

leisure time

knowledge

focus

Wikipedia